The FINANCIAL — Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People’s Liberation Army General Hospital (301 Hospital) in Beijing, China.
The collaboration partners will establish a long-term strategic research partnership in the area of Women’s Healthcare that would benefit patients in China and worldwide.
Under the terms of the agreement, 301 Hospital will receive research funding and their scientists will be able to work at Bayer Schering Pharma’s research facilities in Berlin, Germany.
Bayer Schering Pharma scientists from the recently established Bayer Schering Pharma Global Drug Discovery-Innovation Center China in Beijing will participate in and coordinate the research projects.
According to Bayer, the joint research programs will initially be focused on but not limited to gynecological diseases. Combining the strong expertise of the scientists at 301 Hospital and at Bayer Schering Pharma in Women’s Healthcare, the first project will focus on the establishment and analysis of disease models and disease understanding.
“Working together with the experts from The People’s Liberation Army General Hospital will help us to bring new therapies faster to patients suffering from gynecological diseases, like endometriosis and uterine fibroids. We are looking forward to a successful collaboration.” said Prof. Andreas Busch, Member of the Board of Management at Bayer Schering Pharma and Head of Global Drug Discovery.
301 Hospital is one of the biggest general hospitals in China and has gained a high reputation in gynecology and obstetrics research and expert knowledge in treatment of patients suffering from related diseases.
“Endometriosis and uterine fibroids are severe diseases that significantly compromise the health and quality of life of women. Joining forces will allow us to take advantage of each other’s strengths which will for sure drive the research and innovation in these fields.” said Prof. Guoquan Ren, Head of Medical Management Division, during his welcome address on behalf of 301 officials.
Bayer Schering Pharma on the other side with its strong background and experience in women’s healthcare has a strategic interest in research and development of compounds for gynecological diseases to address the high unmet medical need for new treatment options.